TABLE 1.

Clinical characteristics of the study population.

	Total n = 45
Recipients Age, years, median (IQR) Sex: female, n (%) Cause of ESRD, n (%)  Diabetes  Hypertension  Polycystic disease  Glomerular disease  Interstitial nephritis  Other  Unknown	47 (35–56) 17 (38) 3 (7) 4 (9) 2 (4) 12 (27) 9 (20) 5 (11) 10 (22)
Immunosuppressive therapies for the 2nd transplantation Induction, n (%)  Thymoglobulin  IL-2 receptor blocker Initial maintenance therapy, n (%)  Steroids + tacrolimus + MPA  Steroids + cyclosporin + MPA  Tacrolimus + MPA Associated treatments  Intravenous immunoglobulin  Plasma exchange  Rituximab  Eculizumab	40 (89) 5 (11) 42 (93) 2 (4) 1 (2) 40 (89) 30 (67) 16 (36) 3 (7)
Donors Age, years, median (IQR) Sex: female, n (%) Deceased donor, n (%)	47 (41–59) 23 (51) 39 (87)

IQR, interquartile range; ESRD, end-stage renal disease; DSA, donor specific antibody; IL, interleukin; MPA, mycophenolic acid.